CDR 426D
Alternative Names: CDR-426DLatest Information Update: 17 Sep 2021
Price :
$50 *
At a glance
- Originator Hannover Medical School
- Developer Cardior Pharmaceuticals
- Class Heart failure therapies; Oligonucleotides
- Mechanism of Action MicroRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dilated cardiomyopathy
Most Recent Events
- 17 Sep 2021 Cardior therapeutics in-licenses four patents covering the use of certain miRNAs from Bayerische Patentallianz (Cardior therapeutics pipeline, September 2021)
- 03 Sep 2021 Preclinical trials in Dilated cardiomyopathy in Germany prior to September 2021 (unspecified route) (Cardior Pharmaceuticals pipeline)
- 01 Nov 2018 Cardior Pharmaceuticals has patent protection for use of certain miRNAs